Cancer treatment pioneer Nanobiotix SA (EPN:NANO) has presented new data illustrating how its lead treatment, NBTXR3, can help the body’s immune system fight tumours.
In a presentation to an Immunotherapy workshop co-sponsored by the American Society of Radiation Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC), Nanonbiotix highlighted new data that suggests NBTXR3 generates immunogenic cell death, which could trigger a specific immune response to attack a tumour.
This ability to turn tumours ‘hot’ is seen as key to help a person’s immune system fight their cancer.
New data from an ongoing trial of NBTXR3 in Soft Tissue Sarcoma (STS) showed that in patient tumours there was a significant increase of T cells (CD3+, CD8+) and a marked increase of dendritic cell (CD103+) in those who received NBTXR3 plus radiotherapy arm, as opposed to no differences for those treated with radiotherapy alone.
In studies in mice, meanwhile, NBTXR3 with radiotherapy resulted in a control on the untreated tumours (abscopal effect) not seen just with radiation therapy.
Nanobiotix said that taken together, the results confirm that NBTXR3 plus radiotherapy could efficiently prime the adaptive antitumor immune response, turning “cold” tumours in “hot” tumours.
In addition, the response of the body to NBTXR3 with radiotherapy could effectively make an in-situ vaccine, opening up very promising perspectives in the treatment of local cancer and metastases.